Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Anti-myopia effect of 0.01% atropine over placebo affected spherical equivalent (SE) but not axial length (AL) elongation in both ATOM2 study and LAMP study. It is possible that atropine might exert its effect through changes in corneal properties or lens power.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>To evaluate changes of ocular biometrics in the 0.05%, 0.025%, and 0.01% atropine groups compared to placebo over one year based on the LAMP study.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Design</h3><p>Double-blinded, randomized, placebo-controlled trial.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Participants</h3><p>383 children aged 4 to 12 years, who were randomly assigned to receive 0.05%, 0.025%, 0.01% atropine, or placebo once daily in both eyes and completed the first year of the LAMP study.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Cycloplegic SE, AL, corneal curvatures, and anterior chamber depth (ACD), were measured by IOL Master. Corneal astigmatism and lens power were calculated. The ocular biometric parameters changes were compared among various groups. Contributions to SE progression from ocular parameters were determined and compared among various groups.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Main outcome measures</h3><p>Changes in ocular biometrics and their associations with the changes in SE.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Over one year, changes in AL were 0.20±0.25mm, 0.29±0.20mm, 0.36±0.29mm, and 0.41±0.22mm in 0.05%, 0.025%, 0.01% atropine and placebo, respectively (p<0.001), with a concentration-dependent response. Corneal power remained stable, and its changes were similar across all atropine concentrations, with -0.02±0.14D, -0.01±0.14D, -0.01±0.12D, and 0.01±0.14D in 0.05%, 0.025%, and 0.01% atropine, and placebo, respectively (p = 0.10). Lens power decreased over time in each concentration, but its changes were also similar across all concentrations, with -0.31±0.43D, -0.38±0.47D, -0.40±0.43D, and -0.41±0.43D in 0.05%, 0.025%, 0.01% atropine and placebo respectively (p=0.24). ACD deepened over time, but its changes remained similar across all concentrations (p=0.41). The contributions to SE progression from the ocular biometric changes including changes of K, AL, and lens power after adjusting for age and gender, in each concentration were similar (p>0.05).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Low-concentrations of atropine 0.05%, 0.025%, and 0.01% have no clinical effect on corneal power and lens power. The anti-myopic effects of low-concentration atropine act mainly on reducing AL elongation, and therefore could reduce risk of subsequent myopia complications.</p>

Effect of 0.01% Atropine on Accommodation in Myopic Teenagers

Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression

Effect of Low-dose Atropine on Binocular Vision and Accommodation in Children Aged 6 to 17 Years

Symptoms and ocular findings associated with administration of 0.01% atropine in young adults

The Effect of 0.01% Atropine Eye Drops on the Ocular Surface in Children for the Control of Myopia—The Primary Results from a Six-Month Prospective Study

The Effects of 0.01% Atropine on Adult Myopes’ Contrast Sensitivity

Effects of Atropine 0.01% on Refractive Errors in Children with Myopia.

Short-term effects of ophthalmic topical 0.01% atropine on the ocular surface, pupil size, and subsequent subjective quality of vision in young myopic Chinese adults

Efficacy and Safety of 1% Atropine on Retardation of Moderate Myopia Progression in Chinese School Children

Short-term effects of low-concentration atropine eye drops on pupil size and accommodation in young adult subjects

Short-Term Effects of Atropine 0.01% on the Structure and Vasculature of the Choroid and Retina in Myopic Chinese Children

Effect of 0.01% atropine eye drops combined with different optical treatments to control low myopia in Chinese children

Effects of 0.01% Atropine Instillation Assessed Using Swept-Source Anterior Segment Optical Coherence Tomography

The Effect of 0.01% Atropine Eye Drops Combined with Auricular Acupoint Stimulation on Myopia Progression and Choroidal Thickness: The Preliminary Results from a Randomized Controlled Trial

Treatment of Teenagers Different Types Myopia by Atropoine

Effects on Radius of Curvature and Refractive Power of the Cornea and Crystalline Lens by Atropine 0.01% Eye Drops.

Myopia Controlling using Low Dose Atropine Eye Drop

Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine

Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial

Myopia Control in Caucasian Children with 0.01% Atropine Eye Drops: 1-Year Follow-Up Study

A Randomized Controlled Trial of the Effect of 0.01% Atropine Eye Drops Combined with Auricular Acupoint Stimulation on Myopia Progression